Technical Analysis for INAB - IN8bio, Inc.

Grade Last Price % Change Price Change
D 3.87 -4.44% -0.18
INAB closed down 4.44 percent on Tuesday, January 18, 2022, on 11 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical INAB trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -4.44%
Gilligan's Island Buy Setup Bullish Swing Setup -4.44%
Older End-of-Day Signals for INAB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 19 hours ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

IN8bio, Inc. Description

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Treatment Of Cancer Stem Cell Transplantation Solid Tumor Cancers Acute Leukemia Regenerative Medicine Advanced Therapy Hematopoietic Stem Cell Transplantation

Is INAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.319
52 Week Low 3.58
Average Volume 32,524
200-Day Moving Average 0.00
50-Day Moving Average 6.03
20-Day Moving Average 4.80
10-Day Moving Average 4.30
Average True Range 0.57
ADX 20.14
+DI 13.47
-DI 23.84
Chandelier Exit (Long, 3 ATRs) 5.08
Chandelier Exit (Short, 3 ATRs) 5.29
Upper Bollinger Bands 6.38
Lower Bollinger Band 3.22
Percent B (%b) 0.21
BandWidth 65.90
MACD Line -0.55
MACD Signal Line -0.54
MACD Histogram -0.0025
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.41
Resistance 3 (R3) 4.38 4.18 4.32
Resistance 2 (R2) 4.18 4.04 4.19 4.29
Resistance 1 (R1) 4.02 3.95 4.10 4.05 4.26
Pivot Point 3.82 3.82 3.86 3.83 3.82
Support 1 (S1) 3.66 3.68 3.74 3.69 3.48
Support 2 (S2) 3.46 3.59 3.47 3.45
Support 3 (S3) 3.30 3.46 3.42
Support 4 (S4) 3.33